🚀 VC round data is live in beta, check it out!
ToolGen Valuation Multiples
Discover revenue and EBITDA valuation multiples for ToolGen and similar public comparables like Genfit, Pacific Biosciences, Myriad Genetics, Mirxes Holding and more.
ToolGen Overview
About ToolGen
ToolGen Inc is a biotechnology company, which focuses on the development of genome editing technology. Its products include gRNA/Cas9 purified, gRNA/Cas9, and recombinant Cas9 protein, which offers ready-to-use reagents for genome engineering experiments. The company also offers genome-edited cell line; genome-edited mouse/rat; and genome-edited plant services, as well as surrogate reporter synthesis and in-del analysis services.
Founded
1999
HQ
Employees
22
Website
Financials (FY)
EV
$533M
ToolGen Financials
ToolGen reported last fiscal year revenue of $884K and negative EBITDA of ($23M).
In the same fiscal year, ToolGen generated $771K in gross profit, ($23M) in EBITDA losses, and had net loss of ($25M).
ToolGen P&L
In the most recent fiscal year, ToolGen reported revenue of $884K and EBITDA of ($23M).
ToolGen expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $884K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $771K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 87% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($23M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (2595%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (1782%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($25M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (2814%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ToolGen Stock Performance
ToolGen has current market cap of $552M, and enterprise value of $533M.
Market Cap Evolution
ToolGen's stock price is $63.33.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $533M | $552M | 0.9% | XXX | XXX | XXX | $-2.85 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialToolGen Valuation Multiples
ToolGen trades at 603.1x EV/Revenue multiple, and (23.2x) EV/EBITDA.
ToolGen Financial Valuation Multiples
As of April 18, 2026, ToolGen has market cap of $552M and EV of $533M.
Equity research analysts estimate ToolGen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ToolGen has a P/E ratio of (22.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $552M | XXX | $552M | XXX | XXX | XXX |
| EV (current) | $533M | XXX | $533M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 603.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (23.2x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (33.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 691.3x | XXX | XXX | XXX |
| P/E | — | XXX | (22.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (38.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ToolGen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ToolGen Margins & Growth Rates
ToolGen's revenue in the last fiscal year grew by 47%.
ToolGen's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.8M for the same period.
ToolGen Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 47% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (2595%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (418%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 891% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 24% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 548% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1869% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ToolGen Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| Genfit | XXX | XXX | XXX | XXX | XXX | XXX |
| Pacific Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Myriad Genetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mirxes Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Fulgent Genetics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ToolGen M&A Activity
ToolGen acquired XXX companies to date.
Last acquisition by ToolGen was on XXXXXXXX, XXXXX. ToolGen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ToolGen
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialToolGen Investment Activity
ToolGen invested in XXX companies to date.
ToolGen made its latest investment on XXXXXXXX, XXXXX. ToolGen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ToolGen
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ToolGen
| When was ToolGen founded? | ToolGen was founded in 1999. |
| Where is ToolGen headquartered? | ToolGen is headquartered in South Korea. |
| How many employees does ToolGen have? | As of today, ToolGen has over 22 employees. |
| Is ToolGen publicly listed? | Yes, ToolGen is a public company listed on Korea Exchange. |
| What is the stock symbol of ToolGen? | ToolGen trades under 199800 ticker. |
| When did ToolGen go public? | ToolGen went public in 2014. |
| Who are competitors of ToolGen? | ToolGen main competitors are Genfit, Pacific Biosciences, Myriad Genetics, Mirxes Holding. |
| What is the current market cap of ToolGen? | ToolGen's current market cap is $552M. |
| What is the current revenue of ToolGen? | ToolGen's last fiscal year revenue is $884K. |
| What is the current EV/Revenue multiple of ToolGen? | Current revenue multiple of ToolGen is 603.1x. |
| Is ToolGen profitable? | No, ToolGen is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.